Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
03/11/2020 10:30 AM EDT Dolutegravir-containing regimen exhibited superior safety profile in large, NIH-supported study of pregnant women. |